Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Melatonin prolonged-release (Slenyto®) has been rejected following a resubmission for use in the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2021' on Email Share 'SMC Update - January 2021' on Delicious Share 'SMC Update - January 2021' on Digg Share 'SMC Update - January 2021' on Facebook Share 'SMC Update - January 2021' on reddit Share 'SMC Update - January 2021' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2021”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

vipers